Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 14/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1683479 | 0.86 | NR1H2 (0.76) | NR1H2KDRROCK1 | |
| SCHEMBL1730410 | 0.85 | NR1H2 (0.73) | NR1H2KDRMAP2K1MEN1KMT2A | |
| SCHEMBL17324743 | 0.83 | NR1H2 (0.70) | NR1H2KDRROCK1KMT2AALDH1A1 | |
| SCHEMBL4046774 | 0.82 | NR1H2 (0.70) | NR1H2KDREGFRERBB2MAP2K1 | |
| SCHEMBL14110568 | 0.81 | NR1H2 (0.69) | NR1H2KDREGFRERBB2MAP2K1 | |
| SCHEMBL17321388 | 0.81 | NR1H2 (0.67) | NR1H2KDRROCK1MEN1KMT2A | |
| SCHEMBL4048440 | 0.81 | NR1H2 (0.67) | NR1H2KDREGFRERBB2MAP2K1 | |
| SCHEMBL4225009 | 0.80 | NR1H2 (0.67) | NR1H2KDRROCK1ALDH1A1 | |
| SCHEMBL16646776 | 0.80 | NR1H2 (0.66) | NR1H2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL5606354 | 0.78 | NR1H2 (0.64) | NR1H2KDRROCK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1543009-A4 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-08-08 | — | — | EP | claimed |
| US-20050234060-A1 | Pyrrolotriazine kinase inhibitors | BHIDE RAJEEV S | 2005-10-20 | — | — | US | claimed |
| EP-1543009-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-06-22 | — | — | EP | claimed |
| US-20040063708-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | claimed |
| WO-2004013145-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-12 | — | — | WO | claimed |
| EP-1539763-B1 | AZAINDOLE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-04-13 | — | — | EP | disclosed |
| EP-1543009-A4 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-08-08 | — | — | EP | disclosed |
| EP-1539763-A4 | AZAINDOLE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20060058304-A1 | Azaindole kinase inhibitors | BHIDE RAJEEV S | 2006-03-16 | — | — | US | disclosed |
| US-6969717-B2 | Azaindole kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-29 | — | — | US | disclosed |
| US-20050234060-A1 | Pyrrolotriazine kinase inhibitors | BHIDE RAJEEV S | 2005-10-20 | — | — | US | disclosed |
| US-6951859-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1543009-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-06-22 | — | — | EP | disclosed |
| EP-1539763-A1 | AZAINDOLE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040063708-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| US-20040063707-A1 | Azaindole kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004013145-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-12 | — | — | WO | disclosed |
| WO-2004009601-A1 | AZAINDOLE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063707-A1 | Azaindole kinase inhibitors | FGFR1, FGFR2, FLT1 | NR1H2 3426/4885KDR 5/4885ROCK1 208/4885 |
| US-20060058304-A1 | Azaindole kinase inhibitors | FGFR1, FGFR2, FLT1 | NR1H2 3417/4885KDR 5/4885ROCK1 201/4885 |
| US-20040063708-A1 | Pyrrolotriazine kinase inhibitors | FGFR1, FLT1, FGFR2 | NR1H2 2346/4885KDR 7/4885ROCK1 548/4885 |
| US-20050234060-A1 | Pyrrolotriazine kinase inhibitors | FGFR1, FLT1, FGFR2 | NR1H2 2146/4885KDR 7/4885ROCK1 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.